TrialNature communications2024

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.

Xiaojing Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.